Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | PPARG | P37231 | 8/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | MPC2 | O95563 | 2/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17361063 | 1.00 | MAPT (0.54) | MAPTPPARGFFAR1PPARAITGB3 | |
| SCHEMBL1387126 | 1.00 | MAPT (0.54) | MAPTPPARGFFAR1PPARAITGB3 | |
| Hydrochloric Acid SCHEMBL3867753 | 0.99 | MAPT (0.53) | MAPTPPARGFFAR1PPARAITGB3 | |
| SCHEMBL13908667 | 0.90 | CA2 (0.54) | MAPTPPARGFFAR1PPARAITGB3 | |
| Hydrochloric Acid SCHEMBL4160381 | 0.89 | CA2 (0.53) | MAPTPPARGFFAR1PPARAITGB3 | |
| Potassium Ion SCHEMBL3867740 | 0.88 | MAPT (0.52) | MAPTPPARGFFAR1PPARAMEN1 | |
| SCHEMBL3867994 | 0.88 | MAPT (0.52) | MAPTPPARGFFAR1PPARAMEN1 | |
| SCHEMBL3867997 | 0.88 | MAPT (0.52) | MAPTPPARGFFAR1PPARAMEN1 | |
| Potassium Ion SCHEMBL3867738 | 0.88 | MAPT (0.52) | MAPTPPARGFFAR1PPARAMEN1 | |
| SCHEMBL1386929 | 0.88 | PCNA (0.48) | MAPTPPARGFFAR1PPARAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2987488-A1 | DIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF LUNG DISORDERS | Orchid Chemicals and Pharmaceuticals Ltd (IN) | 2016-02-24 | — | — | EP | claimed |
| EP-1848700-B1 | SALTS OF (S)-2-AMINO-3-{4-[4-(2,4-DIOXO-THIAZOLIDIN-5-YLMETHYL)-PHENOXY]-PHENYL}-PROPIONIC ACID AND ITS METHYL ESTER AS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF OBESITY OR DIABETES | BEXEL PHARMACEUTICALS INC (US) | 2015-12-30 | — | — | EP | claimed |
| EP-2598142-B1 | DIPHENYL ETHER COMPOUNDS FOR USE IN THE TREATMENT OF LIVER DISORDERS | ORCHID CHEMICALS & PHARM LTD (IN) | 2015-12-16 | — | — | EP | claimed |
| US-20140187594-A1 | DIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF LIVER, LUNG DISORDERS, DIABETIC COMPLICATIONS AND CARDIOVASCULAR DISEASES | ORCHID CHEMICALS AND PHARMACEUTICALS LTD (IN) | 2014-07-03 | — | — | US | claimed |
| EP-2598142-A1 | DIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF LIVER, LUNG DISORDERS, DIABETIC COMPLICATIONS AND CARDIOVASCULAR DISEASES | Orchid Chemicals and Pharmaceuticals Ltd (IN) | 2013-06-05 | — | — | EP | claimed |
| WO-2012014218-A1 | DIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF LIVER, LUNG DISORDERS, DIABETIC COMPLICATIONS AND CARDIOVASCULAR DISEASES | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2012-02-02 | — | — | WO | claimed |
| EP-2987488-A1 | DIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF LUNG DISORDERS | Orchid Chemicals and Pharmaceuticals Ltd (IN) | 2016-02-24 | — | — | EP | disclosed |
| EP-1848700-B1 | SALTS OF (S)-2-AMINO-3-{4-[4-(2,4-DIOXO-THIAZOLIDIN-5-YLMETHYL)-PHENOXY]-PHENYL}-PROPIONIC ACID AND ITS METHYL ESTER AS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF OBESITY OR DIABETES | BEXEL PHARMACEUTICALS INC (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-1848700-B1 | SALTS OF (S)-2-AMINO-3-{4-[4-(2,4-DIOXO-THIAZOLIDIN-5-YLMETHYL)-PHENOXY]-PHENYL}-PROPIONIC ACID AND ITS METHYL ESTER AS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF OBESITY OR DIABETES | BEXEL PHARMACEUTICALS INC (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2598142-B1 | DIPHENYL ETHER COMPOUNDS FOR USE IN THE TREATMENT OF LIVER DISORDERS | ORCHID CHEMICALS & PHARM LTD (IN) | 2015-12-16 | — | — | EP | disclosed |
| US-20140187594-A1 | DIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF LIVER, LUNG DISORDERS, DIABETIC COMPLICATIONS AND CARDIOVASCULAR DISEASES | ORCHID CHEMICALS AND PHARMACEUTICALS LTD (IN) | 2014-07-03 | — | — | US | disclosed |
| EP-2598142-A1 | DIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF LIVER, LUNG DISORDERS, DIABETIC COMPLICATIONS AND CARDIOVASCULAR DISEASES | Orchid Chemicals and Pharmaceuticals Ltd (IN) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012014218-A1 | DIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF LIVER, LUNG DISORDERS, DIABETIC COMPLICATIONS AND CARDIOVASCULAR DISEASES | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2012-02-02 | — | — | WO | disclosed |
| US-7521465-B2 | Diphenyl ether derivatives | BEXEL PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187594-A1 | DIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF LIVER, LUNG DISORDERS, DIABETIC COMPLICATIONS AND CARDIOVASCULAR DISEASES | PYGL, CPT1A, GYS2 | MAPT 64/4885PPARG 8/4885FFAR1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.